In Part A , subjects received a single dose of brivanib alaninate ( 800 mg ) either in a fasting state or following ingestion of a high-fat meal ( approximately 951 kcal [ 15 % protein , 33 % carbohydrate , 52 % fat ] ) ; serial blood samples were collected for pharmacokinetic analysis up to 48 h post-dosing .
